An official website of the United States government
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Trial Status: closed to accrual
Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the
efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the
second-line treatment setting in patients with CRC with KRAS G12C mutation.
Inclusion Criteria
Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
Exclusion Criteria
Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
Active brain metastasis
Additional locations may be listed on ClinicalTrials.gov for NCT04793958.
Locations matching your search criteria
United States
California
Los Angeles
Translational Research In Oncology - US Inc (TRIO-US)
